Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.57 |
| ▸ | MAOA | P21397 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | ERN1 | O75460 | 1/20 | 0.50 |
| ▸ | PTPRC | P08575 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21146736 | 0.83 | KMT2A (0.50) | MAOBMAOAKMT2AMEN1RAB9A | |
| SCHEMBL22069990 | 0.83 | KMT2A (0.50) | MAOBMAOAKMT2AMEN1RAB9A | |
| SCHEMBL22071335 | 0.83 | KMT2A (0.50) | MAOBMAOAKMT2AMEN1RAB9A | |
| SCHEMBL2471264 | 0.83 | KDM4E (0.48) | MAOBMAOAKMT2AMEN1RAB9A | |
| SCHEMBL11332668 | 0.83 | MAOB (0.57) | MAOBMAOAKMT2AMEN1RAB9A | |
| SCHEMBL6470760 | 0.80 | MAOB (0.54) | MAOBMAOAKMT2AMEN1RAB9A | |
| SCHEMBL61411 | 0.79 | MAOB (0.71) | MAOBMAOAKMT2AMEN1RAB9A | |
| SCHEMBL12854020 | 0.79 | MAOB (0.71) | MAOBMAOAKMT2AMEN1RAB9A | |
| SCHEMBL11768960 | 0.79 | MAOB (0.53) | MAOBMAOAKMT2AMEN1RAB9A | |
| SCHEMBL11768974 | 0.79 | MAOB (0.53) | MAOBMAOAKMT2AMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2159216-B1 | 3-BUTENYL-1-AMINE DERIVATIVES AND THEIR USE AS Ih MODULORS FOR THE TREATMENT OF PSYCHIATIRC DISORDERS | ORGANON NV (NL) | 2011-10-12 | — | — | EP | disclosed |
| EP-2159216-A1 | Ih - Modulators | N.V. Organon (NL) | 2010-03-03 | — | — | EP | disclosed |
| US-20040229910-A1 | Therapeutic compounds | N.V. ORGANON (NL) | 2004-11-18 | — | — | US | disclosed |
| US-20020037885-A1 | Therapeutic compounds | DIJCKS FREDERICUS ANTONIUS (NL) | 2002-03-28 | — | — | US | disclosed |
| US-6313139-B1 | ADMINISTERING BENZYLAMINE DERIVATIVE FOR THERAPY OF PSYCHIATRIC DISORDER IN MAMMALS | AKZO NOBEL N. V. (NL) | 2001-11-06 | — | — | US | disclosed |
| EP-1077970-A1 | 11-ARYL-BENZO(B)NAPHTHO(2,3-D)FURANS AND 11-ARYL-BENZO(B)NAPHTHO(2,3-D)THIOPHENES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-28 | — | — | EP | disclosed |
| CN-1275909-A | In-modulators | AKZO NOBEL NV (NL) | 2000-12-06 | — | — | CN | disclosed |
| EP-1035843-A2 | I h?-MODULATORS | Akzo Nobel N.V. (NL) | 2000-09-20 | — | — | EP | disclosed |
| US-6110962-A | FOR TREATING INSULIN RESISTANCE, TYPE II DIABETES, HYPERGLYCEMIA, MODULATING INSULIN LEVELS IN MAMMALS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-08-29 | — | — | US | disclosed |
| US-6080773-A | USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS | AKZO NOBEL, N.V. (NL) | 2000-06-27 | — | — | US | disclosed |
| WO-1999058521-A1 | 11-ARYL-BENZO[B]NAPHTHO[2,3-D]FURANS AND 11-ARYL-BENZO[B]NAPHTHO[2,3-D]THIOPHENES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-18 | — | — | WO | disclosed |
| WO-1999018941-A2 | Ih-MODULATORS | AKZO NOBEL N.V. (NL) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229910-A1 | Therapeutic compounds | BDNF, PNMT, SLC18A2 | MAOB 19/4885MAOA 47/4885KMT2A 1807/4885 |
| US-20020037885-A1 | Therapeutic compounds | BDNF, PNMT, SLC18A2 | MAOB 19/4885MAOA 47/4885KMT2A 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.